Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 32Central Nervous System Neoplasms 30Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 27Head and Neck Neoplasms 26Glioblastoma 25Leukemia 24Squamous Cell Carcinoma of Head and Neck 22Lymphoma 22Gliosarcoma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Sarcoma 17Astrocytoma 17Burkitt Lymphoma 14Pancreatic Neoplasms 13Rectal Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Uterine Cervical Neoplasms 11Neuroblastoma 11Lymphoma, Follicular 10Adenocarcinoma of Lung 10Lymphoma, Non-Hodgkin 9Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myeloid, Acute 9Esophageal Neoplasms 9Brain Neoplasms 9Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Laryngeal Neoplasms 8Hodgkin Disease 8

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bladder Urothelial Carcinoma × Radiotherapy × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡